Zeto Inc – Weekly Recap

Zeto Inc, a neurodiagnostics company focused on modernizing electroencephalography in clinical settings, concentrated this week on raising its profile in the point-of-care EEG market. The company highlighted its upcoming participation at the American Clinical Neurophysiology Society Annual Meeting in New Orleans from February 19–22, 2026.

Zeto plans to join the meeting’s inaugural Innovative Technology Lab, a new forum dedicated to point-of-care EEG solutions. CEO Florian Strelzyk is slated to present Zeto ONE, described as a full-montage EEG platform designed for critical care and other demanding hospital environments.

Alongside the technology lab, Zeto will maintain a presence on the exhibition floor at booth 600 to engage directly with clinicians, hospital decision-makers, and key opinion leaders. This dual approach combines clinical demonstration with traditional conference marketing to maximize visibility for its EEG solution.

The company’s messaging emphasizes workflow efficiency and clinical utility in high-acuity settings as key differentiators for Zeto ONE. Positioning the platform within a specialized, clinically rigorous audience may support more favorable adoption and reimbursement dynamics compared with general-purpose EEG offerings.

While no new financial metrics, commercialization milestones, or formal partnership announcements were disclosed, the ACNS engagement underscores ongoing investment in clinical credibility and market development. Stronger relationships with neurologists and health systems could support larger site deployments and a broader commercial pipeline over time.

Overall, the week marked a visibility and branding milestone for Zeto Inc as it prepares to showcase Zeto ONE at a major specialty meeting, potentially laying groundwork that may influence future adoption and growth prospects in the point-of-care EEG segment.